Highlight Therapeutics' BO-112 shows promising results in Phase 2b skin cancer trial
Audio narration · Coming soon
Highlight Therapeutics announced that its lead candidate, BO-112, successfully met the Phase 2b endpoint in treating localized basal cell carcinoma. The trial showed that 61% of evaluable patients achieved a response, indicating potential effectiveness of the skin cancer injections.
Why this matters
PRISM scored this story 60/100 for interest.
Originally published by gnews